SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is a major talking point with significant anticipation surrounding its upcoming showcases of commercial quantum computing solutions at industry events. The community is deeply divided, with many optimistic about the company's potential for broad adoption and future partnerships, while a vocal segment expresses caution regarding valuation and recent executive stock sales. This reflects broader market debate on the commercial readiness and investment risks within the evolving quantum computing sector.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is currently trending following its announced inclusion in the S&P MidCap 400 index, a move expected to generate significant institutional buying pressure and boost market visibility. The community is actively discussing this catalyst as a major inflection point for the pure-play automation leader, anticipating strong long-term growth driven by its Agentic AI solutions and robust financial position. Many investors see this as a key moment, despite some discussions around short-term profit-taking.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending as Sanofi moves to acquire the company for $15.50 per share in a $2.2 billion deal, significantly expanding Sanofi's vaccine pipeline with DVAX's hepatitis B vaccine and developing shingles treatment. The community is celebrating the premium offered, while also speculating on the strategic value Sanofi may see in DVAX's recent licensing of an oral COVID-19 vaccine program. This acquisition has sparked broader conversations about potential interest in smaller biotech companies within the sector.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as gold reaches new all-time highs, driven by persistent central bank buying, geopolitical tensions, and expectations of future monetary easing. The community is actively debating whether this reflects a sustainable "currency reset" or a speculative rally, with many viewing it as an essential safe-haven asset amid global economic uncertainties. Discussions also highlight gold's strong performance compared to other assets like Bitcoin, underscoring its perceived value in a changing financial landscape.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending due to significant insider share accumulation by its CEO, fueling speculation and high retail interest in this low-float Hong Kong-based company. The community is actively debating its extreme volatility and whether it can replicate past parabolic runs seen in similar small-cap plays, despite ongoing discussions about its valuation and business model.

Utopia is a digital paradise designed to reward every step of a user's journey. It is a world where community and cutting-edge technology converge to foster unprecedented freedom, creativity, and tangible value.At the heart of Utopia lies a living, breathing ecosystem where user engagement directly fuels the economy.Participants guide the Utopia girl on her path, drawing her closer to the world's core. With each step, a user's influence grows, as do their potential BNB rewards. Utopia is built on the principle that exploration and active participation should be directly linked to prosperity.The path is for each user to shape, and every discovery brings them closer to the center of it all.

Utopia

Utopia Crypto is trending as its recent listing on a major exchange has sparked widespread bullish sentiment within the community. Investors are actively discussing its potential as a "hidden gem" and future powerhouse, driven by its platform focused on in-game token rewards and ongoing development. The strong conviction points to anticipated significant growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High - Time to Buy?

Esperion Therapeutics (NASDAQ:ESPR) Reaches New 1-Year High - What's Next...

Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) General Counsel Benjamin Looker sold 6,517 shares of Esperion Therapeutics stock in a transaction dated Wednesday, December 17th. The...

Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) CFO Benjamin Halladay sold 7,337 shares of Esperion Therapeutics stock in a transaction dated Wednesday, December 17th. The stock was sold...

Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 12-Month High - Here's Why...

Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR

Two Seas Capital LP raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 43.6% in the second quarter, according to the company in its most recent Form 13F...

Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week High - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Hits New 1-Year High - Should You Buy...

Esperion Therapeutics (NASDAQ:ESPR) Trading 6% Higher - Here's What Happened

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 6% - What's Next...

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...

<ul class="summary-bullets"><li>Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.</li><li>Q3 revenue rose sharply as U.S. product sales and collaboration income continued to strengthen.</li><li>The recent Japan launch and milestones from partner Otsuka added to investor optimism about Esperion’s global expansion.</li></ul>Esperion Therapeutics shares climbed to their highest levels in nearly a year on Tuesday after a bullish initiation from Piper Sandler and fresh progress on the company’s international launch plans helped lift investor sentiment.The stock closed 16.4% higher at $3.69 on Tuesday and edged up another 0.3% in after-hours trading, also logging its best session in almost four months.&nbsp;<h2 class="st-heading-2">Piper Sandler Calls Esperion A Strong Risk-Reward Play</h2>Piper Sandler initiated coverage with an ‘Overweight’ rating and projected a potential 144% upside, describing Esperion as a strong risk-reward play supported by accelerating demand for its cholesterol-lowering drug franchise. The firm highlighted the strength of the company’s bempedoic acid–based therapies, Nexletol and Nexlizet, and said it expects continued rapid volume and sales expansion as physicians shift toward non-statin low-density lipoprotein (LDL)-lowering options, according to a report by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/analyst-ratings/piper-sandler-initiates-esperion-therapeutics-stock-with-overweight-rating-93CH-5124964">Investing</a>.The brokerage pointed to several drivers of long-term growth, including a wide label that covers primary prevention, evolving clinical guidelines that increasingly support the drug class, and broad payer access. A cardiologist-focused survey conducted by the firm reinforced confidence in the therapies’ adoption trajectory.Piper Sandler said it expects Esperion’s products to reach over $650 million in peak U.S. sales, with additional contributions from ex-U.S. royalties, and noted that recent agreements with generic filers provide visibility into exclusivity extending to 2040.Piper Sandler added that Esperion’s risk-reward profile is attractive, noting the stock trades at an enterprise value of roughly 10x estimated 2026 EBITDA, with high visibility into a long-term EBITDA compound annual growth rate above 30% from 2026 through 2031. This long-term view remains intact even as the company reported an EBITDA loss of $29.27 million over the last twelve months.<h2 class="st-heading-2">Esperion Posts Strong Q3 Growth</h2>Esperion reported third-quarter (Q3) total revenue of $87.3 million, an increase of 69% year-on-year, with U.S. net product revenue rising 31% year-on-year to $40.7 million. Collaboration revenue strengthened as well, supported by higher royalty sales and product supply to partners. The company reported an EBITDA loss of $29.27 million, net loss of $31.3 million, and ended the quarter with $92.4 million in cash and cash equivalents. U.S. commercial coverage expanded to more than 90% of commercial lives and over 80% of Medicare beneficiaries, and total prescription volume increased during the period.<h2 class="st-heading-2">Japan Launch Builds Global Momentum</h2>Esperion’s upward momentum comes shortly after a major international milestone. Last week, the company said that its partner Otsuka Pharmaceutical received National Health Insurance Price Listing in Japan and launched Nexletol for hypercholesterolemia and familial hypercholesterolemia. Japan represents the third largest global market for cardiovascular prevention, marking a significant expansion opportunity for Esperion’s cholesterol franchise.Under the agreement, Esperion will receive a $90 million payment tied to Otsuka’s recent regulatory and pricing achievements. The company is also eligible for additional sales milestone payments and tiered royalties of 15% to 30% on net sales in Japan.<h2 class="st-heading-2">Stocktwits Traders Signal Long-Term Confidence</h2>On Stocktwits, retail sentiment for Esperion was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/espr_stock_png_0574a99904.webp" alt="espr stock.png" width="972" height="146"><figcaption>ESPR sentiment and message volume as of November 25 | Source: Stocktwits</figcaption></figure>One user said they did not see a buyout happening soon, noting that Esperion already has a growing commercial drug, additional pipeline assets and a path toward profitability.<stembedurl>https://stocktwits.com/Petey3163/message/637466961</stembedurl>Another user said they expected to remain invested for 18 to 24 months, describing cardiovascular opportunities as early and ESP-2001 as still upcoming, and added that they had built a large position and planned to hold.<stembedurl>https://stocktwits.com/Lskynrd1/message/637466633</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion Therapeutics’ stock</a> has risen 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug 

Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.

Equity

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESPR News

ESPREsperion Therapeutics Inc.